Abstract
Aims and Objectives: The biological dataset was retrieved from two series of α-glucosidase inhibitors synthesized by Rahim et al. and Taha et al. and consisted of a total of 46 (forty-six) α- glucosidase inhibitors.
Methods: The α-glucosidase inhibitory IC50 values (μM; performed against α-glucosidase from Saccharomyces cerevisiae) were converted into negative logarithmic units (pIC50). The CoMFA and CoMSIA models were developed using 37 as a training set, and externally validated using 9 as a test set. The CoMFA models MMFF94 were generated, ranging from 3.4661 to 5.2749 using leave-oneout PLS analysis cross-validated correlation coefficient q2 0.787, a high non-cross-validated correlation coefficient r2 0.819, with a low Standard Error Estimation (SEE) 0.041, F value 1316.074 and r2pred 0.996.
Results: The steric and electrostatic fields contributions were 0.507 and 0.493, respectively. The CoMSIA model q2 0.805, r2 0.833 was attained, (SEE) 0.065, F value 520.302 and r2pred 0.990. Contribution of steric, electrostatic, hydrophobic, donor and acceptor fields was 0.151, 0.268, 0.223, 0.234, 0.124, respectively.
Conclusion: The HQSAR model of the training set exhibits a significant cross-validated correlation coefficient q2 0.800 and non-cross-validated correlation coefficient r2 0.943.
Keywords: CoMFA, CoMSIA, HQSAR, pharmacophore mapping, docking, α-glucosidase inhibitor.
Current Drug Discovery Technologies
Title:Molecular Modelling Studies on Thiazole-Based α-Glucosidase Inhibitors Using Docking and CoMFA, CoMSIA and HQSAR
Volume: 18 Issue: 6
Author(s): Deshbandhu Joshi*, Shourya Yadav, Rajesh Sharma, Mitrunjaya Pandya and Raghvendra Singh Bhadauria
Affiliation:
- School of Pharmacy, Devi Ahilya Vishwavidyalya Takshashila Campus, Khandwa Road, Indore-452001 Madhya Pradesh,India
Keywords: CoMFA, CoMSIA, HQSAR, pharmacophore mapping, docking, α-glucosidase inhibitor.
Abstract:
Aims and Objectives: The biological dataset was retrieved from two series of α-glucosidase inhibitors synthesized by Rahim et al. and Taha et al. and consisted of a total of 46 (forty-six) α- glucosidase inhibitors.
Methods: The α-glucosidase inhibitory IC50 values (μM; performed against α-glucosidase from Saccharomyces cerevisiae) were converted into negative logarithmic units (pIC50). The CoMFA and CoMSIA models were developed using 37 as a training set, and externally validated using 9 as a test set. The CoMFA models MMFF94 were generated, ranging from 3.4661 to 5.2749 using leave-oneout PLS analysis cross-validated correlation coefficient q2 0.787, a high non-cross-validated correlation coefficient r2 0.819, with a low Standard Error Estimation (SEE) 0.041, F value 1316.074 and r2pred 0.996.
Results: The steric and electrostatic fields contributions were 0.507 and 0.493, respectively. The CoMSIA model q2 0.805, r2 0.833 was attained, (SEE) 0.065, F value 520.302 and r2pred 0.990. Contribution of steric, electrostatic, hydrophobic, donor and acceptor fields was 0.151, 0.268, 0.223, 0.234, 0.124, respectively.
Conclusion: The HQSAR model of the training set exhibits a significant cross-validated correlation coefficient q2 0.800 and non-cross-validated correlation coefficient r2 0.943.
Export Options
About this article
Cite this article as:
Joshi Deshbandhu *, Yadav Shourya, Sharma Rajesh , Pandya Mitrunjaya and Bhadauria Singh Raghvendra , Molecular Modelling Studies on Thiazole-Based α-Glucosidase Inhibitors Using Docking and CoMFA, CoMSIA and HQSAR, Current Drug Discovery Technologies 2021; 18 (6) : e130921187100 . https://dx.doi.org/10.2174/1570163817666201022111213
| DOI https://dx.doi.org/10.2174/1570163817666201022111213 |
Print ISSN 1570-1638 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
Call for Papers in Thematic Issues
Advancements in Computational Methods for Drug Design
This thematic issue delves into the cutting-edge computational methodologies revolutionizing drug design. Emphasizing the integration of in silico techniques, this collection highlights advancements in some computational methods, as: molecular docking, molecular dynamics, QSAR (Quantitative Structure-Activity Relationship) and free energy calculations. These approaches enhance the efficiency of drug discovery, reduce costs, ...read more
Disease Modelling: Emerging Frontiers in Disease Modelling: Data to Drug Discovery in Bioinformatics in Precision Medicine and Health Science
The special issue on "Emerging Frontiers in Disease Modelling: Data to Drug Discovery in Bioinformatics in Precision Medicine and Health Science" aims to explore the transformative role of bioinformatics in bridging the gap between extensive biological data and the development of targeted therapies. This issue will highlight cutting-edge research and ...read more
Novel Drug Delivery Therapeutics: Opportunities and Challenges for Combating Diseases
The field of drug delivery therapeutics has undergone significant transformation with the emergence of innovative technologies designed to enhance therapeutic efficacy and patient outcomes. As traditional drug administration methods encounter limitations in terms of efficacy, safety, and patient compliance, novel drug delivery systems offer promising solutions to these challenges. Advancements ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond
Current Drug Metabolism Mixed Micelles as Nano Polymer Therapeutics of Docetaxel: Increased In vitro Cytotoxicity and Decreased In vivo Toxicity
Current Drug Delivery New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors
Current Pharmaceutical Design Novel Chelators Targeting Cell Cycle Arrest, Acetylcholinesterase, and Monoamine Oxidase for Alzheimer's Therapy
Current Drug Targets Atrial Remodeling and Novel Pharmacological Strategies for Antiarrhythmic Therapy in Atrial Fibrillation
Current Medicinal Chemistry Effects of Natural Products on Contact Dermatitis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Engineered Peptides for Applications in Cancer-Targeted Drug Delivery and Tumor Detection
Mini-Reviews in Medicinal Chemistry Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors as Anti-Angiogenic Agents in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Tetracyclines and Pulmonary Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Subthreshold Diode Micropulse Laser Photocoagulation (SDM) as Invisible Retinal Phototherapy for Diabetic Macular Edema: A Review
Current Diabetes Reviews Hybrid-Based Multi-Target Ligands for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design Protein-Directed Immobilization of Phosphocholine Ligands on a Gold Surface for Multivalent C-Reactive Protein Binding
Current Topics in Medicinal Chemistry Adrenomedullin Function in Vascular Endothelial Cells: Insights from Genetic Mouse Models
Current Hypertension Reviews Current Concepts on Cardiovascular Stent Devices
Mini-Reviews in Medicinal Chemistry Large A-V Fistula: Pathophysiological Consequences and Therapeutic Perspectives
Current Vascular Pharmacology Bioactive Molecules Used in Biomimetic Scaffolds: The Recent Progress in the Angiogenesis of Thick Tissue Engineering
Current Tissue Engineering (Discontinued) Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities
Current Pharmaceutical Design Overcoming hERG Affinity in the Discovery of Maraviroc; A CCR5 Antagonist for the Treatment of HIV
Current Topics in Medicinal Chemistry






